Analyst Says He Likes AbbVie (ABBV) Amid 'Attractive' Valuation
“If I’m a little nervous, just a little nervous, I’m going to go with something that’s kind of on the safe side. AbbVie Inc (NYSE:ABBV).
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 24,222 | $5,608,407 | -3% | 2.62% |
| 2. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,923 | $445,251 | 0.01% | |
| 3. | Sivik Global Healthcare Krishen Sud | 20,000 | $4,631 | 1.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $198.42 | 42,370 | $8,407,055.40 | 177,292 | 2025-08-12 | Filing | |
| $198.59 | 10,061 | $1,998,013.99 | 58,247 | 2025-08-05 | Filing | |
| $198.27 | 3,234 | $641,238.89 | 68,308 | 2025-08-05 | Filing | |
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,323,036 | $769,415,756 | 1.11% | |
| 2. | 3,225,427 | $746,815,368 | 1.02% | |
| 3. | 2,455,380 | $568,184,890 | 0.57% | |
| 4. | 2,324,286 | $538,165,180 | 1.83% | |
| 5. | 1,963,460 | $454,619,526 | 0.46% |
News See All
AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV.
10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts
Markets are getting jittery after JPMorgan CEO Jamie Dimon pointed to potential cracks in the credit markets following a few regional bank earnings.
Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)
On October 14, Cantor Fitzgerald reaffirmed its Overweight rating and $250 price target for AbbVie Inc.
11 Defensive Healthcare Dividend Stocks To Buy Now
US healthcare stocks have been under mounting pressure this year, largely due to policies introduced by the Trump administration.
Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade
At the beginning of this month, AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101’s food interaction and a Phase 2 study of Budigalimab and/or ABBV-382 on HIV.
AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts
As part of its $10 billion U.S. capital expenditure strategy to increase biologics manufacturing capacity, AbbVie Inc.
Jim Cramer's Recession-Proof Stock Picks
The recent political gridlock in the U.S. is making investors nervous about the impact this would have on their investments.
Bernstein Remains a Hold on AbbVie Inc. (ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
